Friday, September 18th | 1 Tishri 5781

Subscribe
May 12, 2020 9:31 am

Covid-19 Gave Medtech a Push Forward, Says Israel’s EarlySense CTO

avatar by CTech Staff

Israeli firefighters wearing protective clothes disinfect Ichilov Hospital in Tel Aviv, on March 20, 2020, as part of measures to prevent the spread of the COVID-19 virus. Photo: Flash90.

CTech – If you ask Guy Meger, the chief technology officer and general manager of Israeli medtech company EarlySense, the coronavirus (Covid-19) outbreak has had one positive impact on healthcare systems around the world: The pandemic helped eliminate things that were blocking innovation in the medtech sector, Meger said in a recent interview with 30 Minutes or Less, a podcast dedicated to the Israeli tech scene.

The pandemic highlighted what happens when you let healthcare be left behind in terms of new technologies, Meger said. “Suddenly,” he added, “no one could bear the thought of looking in the mirror a year from now and knowing that there was a technology that could have saved lives that was not adopted due to bureaucratic hurdles.”

While previous partnerships with hospitals in the US took years to sign, the coronavirus outbreak meant EarlySense managed to secure a deal with the prestigious Mount Sinai Medical Center in New York in just 30 hours, Meger said. In the past, it was impossible to even get them on the phone, he added.

Founded in 2004 and based in central Israeli town Ramat Gan, EarlySense develops a patient monitoring system capable of registering parameters such as heart and respiratory rates, motion, and quality of sleep. The system uses an ultra-sensitive sensor that is placed under the patient’s mattress and collects data in the background. The company’s products are approved for medical use in both the US and the European Union.

Related coverage

September 18, 2020 2:08 pm
0

Report: Trump Administration Seeking Direct Israel-Lebanon Talks on Maritime Border

The Trump administration is once again seeking direct talks between Israel and Lebanon on setting their maritime border -- which...

The idea first came to EarlySense’s four co-founders when they were dealing with a common problem, Meger said. Each of them had a child suffering from asthma and they wanted to be able to make sure the child is able to breathe regularly while sleeping, without having to disturb them.

This market, however, was too small, Meger said, and the team soon realized the technology can be used in hospitals for monitoring patients at night. A night nurse can only check on each patient once or twice during their shift, but EarlySense’s system can offer constant monitoring and alerts on any changes.

With the vast amounts of data its system collects, Meger said, EarlySense uses artificial intelligence algorithms to predict when a patient’s condition is likely to deteriorate. According to him, the system can detect early signs of heart or respiratory failure hours before they become life-threatening.

When it comes to Covid-19, EarlySense’s system lets doctors know exactly how their patients are doing and detect signs of deterioration without having to conduct a face-to-face examination and expose themselves to the virus, Meger said. In coronavirus departments that use EarlySense’s technology, there have been no cases of medical staff contracting the virus, he added.

According to Mager, EarlySense’s system is in use in 250 hospitals and medical institutions in the US and seven hospitals in Israel, including the Sheba Medical Center, which was the first to set up a coronavirus department in the country. Sheba contacted EarlySense when it was setting up the department and other hospitals in the country followed suit.

EarlySense also has a partnership with Florida-based medical equipment company HERO Medical, and for the past two years, its latest model has come with the system pre-installed and activated, Meger said.

EarlySense has 120 employees, 65 of whom are based in Israel, and has raised $160 million to date, according to Mager.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.